A California bankruptcy court has approved a $46.75 million (£35 million) compensation settlement for people affected by the 2023 data breach at genetic testing company 23andMe. The ruling requires Chrome Holding, which acquired 23andMe’s assets following the company’s bankruptcy, to fund the settlement. Chrome Holding, operating as TTAM Research Institute and led by 23andMe co-founder…
California Attorney General Rob Bonta has announced legal action against Chrome Holding, the company that succeeded genetic testing firm 23andMe, over allegations linked to a major data breach that compromised the personal information of millions of users. The lawsuit follows an investigation by the California Department of Justice, which concluded that 23andMe failed to adequately…
The UK’s data protection watchdog has fined DNA testing firm 23andMe £2.31 million for failing to adequately protect the personal information of thousands of users affected by a major data breach in 2023. According to the Information Commissioner’s Office (ICO), the breach – which impacted more than 155,000 UK residents – exposed highly sensitive data,…
A nonprofit organization led by Anne Wojcicki, co-founder and former CEO of genetic testing company 23andMe, has successfully secured the acquisition of the company after it filed for bankruptcy in March. Wojcicki’s California-based TTAM Research Institute agreed to purchase 23andMe for $305 million, surpassing a competing bid from Regeneron Pharmaceuticals, which had offered $256 million….
Biotech giant Regeneron Pharmaceuticals has announced plans to acquire genetic testing firm 23andMe for $256 million, following the company’s bankruptcy proceedings. The deal was confirmed on Monday and is expected to be finalized in the third quarter of 2025. The acquisition comes after 23andMe filed for bankruptcy in March amid falling demand for its ancestry…
Genetic testing company 23andMe has filed for Chapter 11 bankruptcy protection, citing financial difficulties and a need to restructure for a potential sale. The move comes after years of struggling to establish a sustainable business model. As part of the bankruptcy filing, CEO Anne Wojcicki has stepped down, effective immediately, though she will remain on…
Three years after reaching unprecedented heights with a market valuation surpassing Apple’s, DNA-testing firm 23andMe now finds itself in a struggle to survive. Once celebrated for its innovation in consumer genetic testing and its high-profile clientele, 23andMe has seen its stock price plummet to just under $5, a mere fraction of its peak at $321….
